Labadie, Kevin P.
Kreuser, Shannon A.
Brempelis, Katherine J. http://orcid.org/0000-0002-9255-2608
Daniel, Sara K.
Jiang, Xiuyun
Sullivan, Kevin M. http://orcid.org/0000-0001-7455-2308
Utria, Alan F.
Kenerson, Heidi L.
Kim, Teresa S. http://orcid.org/0000-0002-6040-7748
Crane, Courtney A.
Pillarisetty, Venu G. http://orcid.org/0000-0002-1162-9643
Article History
Received: 14 November 2022
Revised: 4 May 2023
Accepted: 19 May 2023
First Online: 9 June 2023
COMPETING INTERESTS
: The authors declare that that they have read and understood the policy on declarations of interest. VGP is a member of the scientific advisory board for TriSalus Life Sciences. He served as a consultant for Merck & Company in 2018, GlaxoSmithKline in 2019, Imvax in 2019, Takeda in 2020, Umoja and Sensei in 2022. He has had research funding from AstraZeneca (completed), Ipsen (completed), Merck (completed), NGM (completed), and OncoResponse (current). The funders had no role in the conceptualization, design, data collection, analysis, decision to publish or preparation of the manuscript. CAC is an inventor on issued patent US20170087185A1 “Genetic engineering of macrophages for immunotherapy”.
: All investigations were performed according to the principles expressed in the Declaration of Helsinki. Samples for slice culture were procured from patients undergoing hepatic or pancreatic resection who provided prior written-informed consent under research protocol (no. 1852) approved by the University of Washington Institutional Review Board.